Medicine and Dentistry
Neuroendocrine Tumor
100%
Neoplasm
35%
Neuroendocrine Carcinoma
18%
Positron Emission Tomography
18%
Copper 64
15%
Disease
14%
Somatostatin Receptor
13%
Positron Emission Tomography-Computed Tomography
13%
Carcinoid
12%
Surgery
12%
Metastatic Carcinoma
12%
Radionuclide Therapy
11%
Overall Survival
11%
Positron Emission Tomography
11%
Peptide Receptor
11%
Diagnosis
10%
Progression Free Survival
9%
Radioactive Tracer
9%
Gallium 68
7%
Chromogranin A
7%
Cohort Analysis
7%
Primary Tumor
7%
Symptom
7%
Biological Marker
6%
Fluorodeoxyglucose F 18
6%
Pancreas Islet Cell Tumor
6%
Fluorine-18
6%
Recurrent Disease
6%
Liver Metastasis
5%
Gastroenteropancreatic Neuroendocrine Tumor
5%
Lutetium 177
5%
Etoposide
5%
Prognostic Factor
5%
Tumor Progression
5%
Keyphrases
Neuroendocrine Tumor
48%
Neuroendocrine Neoplasms
34%
64Cu-DOTATATE
15%
Tumor
14%
Positron Emission Tomography-computed Tomography (PET-CT)
12%
Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
12%
Neuroendocrine Carcinoma
12%
Histamine
12%
Overall Survival
11%
Peptide Receptor Radionuclide Therapy
11%
Ki-67 Index
11%
Chromogranin A
10%
DOTATATE PET
10%
Pancreatic Neuroendocrine Tumors (pNETs)
10%
Small Intestinal Neuroendocrine Tumors
9%
Head-to-head Comparison
9%
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
9%
Ki-67
8%
Gallium-68
8%
Progression-free Survival
8%
DOTATATE
7%
Stress-induced
7%
Pancreas
6%
Copenhagen
6%
Metastasis
6%
Arginine Vasopressin
6%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
6%
Vasopressin
6%
Multiple Endocrine Neoplasia Type 1 (MEN1)
6%
Somatostatin Receptor Imaging
5%
Primary Tumor
5%
Prognostic Factors
5%
Positron Emission Tomography
5%
Tumor Patients
5%
Somatostatin Analogs
5%
Somatostatin Receptor
5%
β-endorphin
5%
